Cargando…
Rimonabant: the evidence for its use in the treatment of obesity and the metabolic syndrome
INTRODUCTION: Obesity and overweight affect over 1 billion people worldwide and are leading causes of morbidity and mortality. Clinical features of obesity converge with those of the metabolic syndrome and type 2 diabetes, greatly increasing the risk of long-term adverse outcomes. AIMS: To review th...
Autores principales: | Waterlow, Mark, Chrisp, Paul |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3012438/ https://www.ncbi.nlm.nih.gov/pubmed/21221184 |
Ejemplares similares
-
Bevacizumab: the evidence for its clinical potential in the treatment of nonsmall cell lung cancer
por: Haslam, Sonya, et al.
Publicado: (2007) -
Vildagliptin: the evidence for its place in the treatment of type 2 diabetes mellitus
por: Profit, Louise, et al.
Publicado: (2008) -
Aprepitant: the evidence for its place in the prevention of chemotherapy-induced nausea and vomiting
por: Chrisp, Paul
Publicado: (2007) -
Ciclesonide in persistent asthma: the evidence of its therapeutic value
por: Kenreigh, Charlotte A., et al.
Publicado: (2006) -
Prucalopride: the evidence for its use in the treatment of chronic constipation
por: Coremans, Georges
Publicado: (2008)